Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! By
Design and Synthesis of Novel Quinazolinone-1,2,3-Triazole Hybrids As New Anti-Diabetic Agents: In Vitro Α-Glucosidase Inhibition, Kinetic, and Docking Study Publisher Pubmed



Saeedi M1, 2 ; Mohammadikhanaposhtani M3 ; Pourrabia P2 ; Razzaghi N4 ; Ghadimi R5 ; Imanparast S6 ; Faramarzi MA6 ; Bandarian F7 ; Esfahani EN7 ; Safavi M8 ; Rastegar H9 ; Larijani B10 ; Mahdavi M10 ; Akbarzadeh T2, 4
Authors

Source: Bioorganic Chemistry Published:2019


Abstract

A novel series of quinazolinone-1,2,3-triazole hybrids 10a-p were designed, synthesized, and evaluated for their in vitro α-glucosidase inhibitory activity leading to efficient anti-diabetic agents. All synthesized compounds exhibited good inhibitory activity against yeast α-glucosidase (IC 50 values in the range of 181.0–474.5 µM) even much more potent than standard drug acarbose (IC 50 = 750.0). Among them, quinazolinone-1,2,3-triazoles possessing 4-bromobenzyl moiety connected to 1,2,3-triazole ring (10g and 10p) demonstrated the most potent inhibitory activity towards α-glucosidase. Compound 10g inhibited α-glucosidase in a competitive manner with K i value of 117 µM. Furthermore, the binding modes of the most potent compounds 10g and 10p in the α-glucosidase active site was studied through in silico docking studies. Also, lack of cytotoxicity of compounds 10g and 10p was confirmed via MTT assay. © 2018 Elsevier Inc.
Other Related Docs